These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1142 related articles for article (PubMed ID: 27188934)

  • 1. Alzheimer's disease.
    Masters CL; Bateman R; Blennow K; Rowe CC; Sperling RA; Cummings JL
    Nat Rev Dis Primers; 2015 Oct; 1():15056. PubMed ID: 27188934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
    Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
    J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marking the markers of Alzheimer's: too good to diagnose, too bad to use?
    Olah Z; Pakaski M; Janka Z; Kalman J
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):165-76. PubMed ID: 22987730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.
    Höglund K; Syversen S; Lewczuk P; Wallin A; Wiltfang J; Blennow K
    Exp Brain Res; 2005 Jul; 164(2):205-14. PubMed ID: 15937702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
    Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
    Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Expression of Amyloid Precursor Protein and the Ratio of Secreted Amyloid Beta 42 to Amyloid Beta 40 in SH-SY5Y Cells Stably Transfected with Wild-Type, Single-Mutant and Double-Mutant Forms of the APP Gene for the Study of Alzheimer's Disease Pathology.
    Pahrudin Arrozi A; Shukri SNS; Wan Ngah WZ; Mohd Yusof YA; Ahmad Damanhuri MH; Makpol S
    Appl Biochem Biotechnol; 2017 Nov; 183(3):853-866. PubMed ID: 28417423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives.
    de Castro AA; da Cunha EFF; Pereira AF; Soares FV; Leal DHS; Kuca K; Ramalho TC
    Curr Alzheimer Res; 2018; 15(12):1161-1178. PubMed ID: 30101709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
    Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
    Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.
    Castello MA; Soriano S
    Ageing Res Rev; 2014 Jan; 13():10-2. PubMed ID: 24252390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.
    Suárez-Calvet M; Belbin O; Pera M; Badiola N; Magrané J; Guardia-Laguarta C; Muñoz L; Colom-Cadena M; Clarimón J; Lleó A
    J Neurochem; 2014 Jan; 128(2):330-9. PubMed ID: 24117942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid biomarkers in Alzheimer's disease.
    Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
    Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease.
    Debatin L; Streffer J; Geissen M; Matschke J; Aguzzi A; Glatzel M
    Neurodegener Dis; 2008; 5(6):347-54. PubMed ID: 18349519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.